Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP RANDOMET 2017 for stage IV childhood renal tumors
NL-OMON59109Phase 3Recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- May 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, actinomycin D, doxorubicin, carboplatin and etoposide in Nephroma and Wilms' tumor (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Metastatic rapid response rate after 6 weeks of preoperative chemotherapy. Started May 2023; status: recruiting.
02
Drugs
vincristineactinomycin Ddoxorubicincarboplatinetoposide
03
Conditions
NephromaWilms' tumor
Beyond the preview
Go deeper on NL-OMON59109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59109.